用于慢性自发性荨麻疹监测的数字视觉模拟量表的有效性、可靠性和响应性：CRUSE®移动医疗研究。

IF 12.6 1区医学 Q1 ALLERGY

Allergy Pub Date : 2024-10-24 DOI:10.1111/all.16371

Bernardo Sousa-Pinto,Aiste Ramanauskaite,Sophia Neisinger,Ellen Witte-Händel,Ana M Gimenez-Arnau,Carole Guillet,Claudio Alberto S Parisi,Constance H Katelaris,Daria Fomina,Désirée Larenas-Linnemann,Elizabeth García,Emek Kocatürk,Frank Siebenhaar,Hermenio Lima,Igor Kaidashev,Iman Nasr,Isabel Ogueta Canales,Ivan Cherrez Ojeda,Jacques Hébert,Jean Bousquet,Jonathan A Bernstein,Jonny Peter,Jorge Sanchez,Jose Ignacio Larco Sousa,Kanokvalai Kulthanan,Karsten Weller,Kiran Godse,Krzysztof Rutkowski,Lasma Lapina,Laurence Bouillet,Leo Lianyi Han,Luis Felipe Ensina,Margarida Gonçalo,Markus Magerl,Martijn van Doorn,Martin Metz,Maryam Khoshkhui,Michihiro Hide,Murat Türk,Nataļja Kurjāne,Niall Conlon,Pascale Salameh,Pavel Kolkhir,Riccardo Asero,Roman Stepanenko,Sabine Altrichter,Sara Gil-Mata,Simon Francis Thomsen,Torsten Zuberbier,Vladyslav Tsaryk,Young-Min Ye,Zenon Brzoza,Zuotao Zhao,Marcus Maurer

{"title":"用于慢性自发性荨麻疹监测的数字视觉模拟量表的有效性、可靠性和响应性：CRUSE®移动医疗研究。","authors":"Bernardo Sousa-Pinto,Aiste Ramanauskaite,Sophia Neisinger,Ellen Witte-Händel,Ana M Gimenez-Arnau,Carole Guillet,Claudio Alberto S Parisi,Constance H Katelaris,Daria Fomina,Désirée Larenas-Linnemann,Elizabeth García,Emek Kocatürk,Frank Siebenhaar,Hermenio Lima,Igor Kaidashev,Iman Nasr,Isabel Ogueta Canales,Ivan Cherrez Ojeda,Jacques Hébert,Jean Bousquet,Jonathan A Bernstein,Jonny Peter,Jorge Sanchez,Jose Ignacio Larco Sousa,Kanokvalai Kulthanan,Karsten Weller,Kiran Godse,Krzysztof Rutkowski,Lasma Lapina,Laurence Bouillet,Leo Lianyi Han,Luis Felipe Ensina,Margarida Gonçalo,Markus Magerl,Martijn van Doorn,Martin Metz,Maryam Khoshkhui,Michihiro Hide,Murat Türk,Nataļja Kurjāne,Niall Conlon,Pascale Salameh,Pavel Kolkhir,Riccardo Asero,Roman Stepanenko,Sabine Altrichter,Sara Gil-Mata,Simon Francis Thomsen,Torsten Zuberbier,Vladyslav Tsaryk,Young-Min Ye,Zenon Brzoza,Zuotao Zhao,Marcus Maurer","doi":"10.1111/all.16371","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nCRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs.\r\n\r\nMETHODS\r\nWe evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU ('VAS urticaria'), VAS for the impact of urticaria on work/school productivity ('VAS productivity') and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test-retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods.\r\n\r\nRESULTS\r\nWe included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test-retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D.\r\n\r\nCONCLUSION\r\nDaily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test-retest reliability and responsiveness.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"14 1","pages":""},"PeriodicalIF":12.6000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study.\",\"authors\":\"Bernardo Sousa-Pinto,Aiste Ramanauskaite,Sophia Neisinger,Ellen Witte-Händel,Ana M Gimenez-Arnau,Carole Guillet,Claudio Alberto S Parisi,Constance H Katelaris,Daria Fomina,Désirée Larenas-Linnemann,Elizabeth García,Emek Kocatürk,Frank Siebenhaar,Hermenio Lima,Igor Kaidashev,Iman Nasr,Isabel Ogueta Canales,Ivan Cherrez Ojeda,Jacques Hébert,Jean Bousquet,Jonathan A Bernstein,Jonny Peter,Jorge Sanchez,Jose Ignacio Larco Sousa,Kanokvalai Kulthanan,Karsten Weller,Kiran Godse,Krzysztof Rutkowski,Lasma Lapina,Laurence Bouillet,Leo Lianyi Han,Luis Felipe Ensina,Margarida Gonçalo,Markus Magerl,Martijn van Doorn,Martin Metz,Maryam Khoshkhui,Michihiro Hide,Murat Türk,Nataļja Kurjāne,Niall Conlon,Pascale Salameh,Pavel Kolkhir,Riccardo Asero,Roman Stepanenko,Sabine Altrichter,Sara Gil-Mata,Simon Francis Thomsen,Torsten Zuberbier,Vladyslav Tsaryk,Young-Min Ye,Zenon Brzoza,Zuotao Zhao,Marcus Maurer\",\"doi\":\"10.1111/all.16371\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nCRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs.\\r\\n\\r\\nMETHODS\\r\\nWe evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU ('VAS urticaria'), VAS for the impact of urticaria on work/school productivity ('VAS productivity') and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test-retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods.\\r\\n\\r\\nRESULTS\\r\\nWe included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test-retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D.\\r\\n\\r\\nCONCLUSION\\r\\nDaily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test-retest reliability and responsiveness.\",\"PeriodicalId\":122,\"journal\":{\"name\":\"Allergy\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":12.6000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/all.16371\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/all.16371","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

背景CRUSE®是一款应用程序，它允许慢性自发性荨麻疹（CSU）患者通过使用视觉模拟量表（VAS）来监测日常疾病活动。我们旨在确定 CRUSE® VASs 的并发有效性、可靠性、响应性和最小重要差异 (MID)：我们评估了三种日常 VAS 的特性：患者受 CSU 影响程度的 VAS（"荨麻疹 VAS"）、荨麻疹对工作/学习效率影响的 VAS（"生产力 VAS"）以及 EQ-5D 的 VAS。通过测量每种 VAS 与荨麻疹活动评分（UAS）之间的关联性来评估并发有效性。根据用户在同一天内提供多份每日问卷的数据，确定了评分者内部的可靠性。在临床稳定和临床不稳定的用户中分别测试了重测可靠性和响应性（改变能力）。结果我们共纳入了 5938 名患者（67380 天）。并发有效性很高，VAS荨麻疹与 UAS 评分的相关性比其他 VAS 更强。评分者内部的可靠性也很高，所有 VAS 的类内相关系数 (ICC) 均高于 0.950。测试间隔可靠性和响应性均达到中等水平，其中 VAS EQ-5D 的可靠性 ICC 最高，VAS 荨麻疹的响应性最高。结论 CRUSE® 应用程序中的 CSU 日常 VAS 具有较高的并发有效性和评分者内部可靠性，以及中等偏上的测试再测可靠性和响应性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study.

BACKGROUND CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. METHODS We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU ('VAS urticaria'), VAS for the impact of urticaria on work/school productivity ('VAS productivity') and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test-retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. RESULTS We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test-retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. CONCLUSION Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test-retest reliability and responsiveness.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.